Muscle wasting in cancer cachexia: Clinical implications, diagnosis, and emerging treatment strategies

Annual Review of Medicine

Volumn 62, Issue , 2011, Pages 265-279

  Dodson, Shontelle ^a   Baracos, Vickie E ^b   Jatoi, Aminah ^c   Evans, William J ^d   Cella, David ^e   Dalton, James T ^a   Steiner, Mitchell S ^a  

^a GTx Inc   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MAYO CLINIC   (United States)

^d GLAXOSMITHKLINE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

anabolic; body composition; quality of life; sarcopenia; selective androgen receptor modulator; skeletal muscle metabolism

Indexed keywords

ALD 518; ANAMORELIN; ANDARINE; ANTIVIRUS AGENT; APPETITE STIMULANT; AVR 118; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2; GAMMA INTERFERON; GTX 007; GTX 024; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MEGESTROL ACETATE; OSTARINE; OXANDROLONE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARM CIRCUMFERENCE; ARTICLE; BODY COMPOSITION; CACHEXIA; CANCER CACHEXIA; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; MUSCLE ATROPHY; MUSCLE METABOLISM; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SKELETAL MUSCLE; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANABOLIC AGENTS; CACHEXIA; CLINICAL TRIALS AS TOPIC; CYTOKINES; ENERGY METABOLISM; FEMALE; HUMANS; MALE; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NEOPLASMS; QUALITY OF LIFE;

EID: 79551614788     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-med-061509-131248     Document Type: Article

References (83)

1. Morley JE, Thomas DR, Wilson MM. 2006. Cachexia: pathophysiology and clinical relevance. Am. J. Clin. Nutr. 83:735-43
2. Tan BH, Fearon KC. 2008. Cachexia: prevalence and impact in medicine. Curr. Opin. Clin. Nutr. Metab. Care 11:400-7
3. Klaude M, Fredriksson K, Tjader I, et al. 2007. Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin. Sci. (Lond.) 112:499-506
4. Evans WJ. 2010. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am. J. Clin. Nutr.91:1123S-27S
5. Evans WJ, Morley JE, Argiles J, et al. 2008. Cachexia: a new definition. Clin. Nutr. 27:793-99
6. Bruera E. 1997. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ 315:1219-22
7. Dewys WD, Begg C, Lavin PT, et al. 1980. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69:491-97
8. World Health Organization. 2009. Cancer key facts. http://www.who.int/ mediacentre/factsheets/ fs297/en/index.html
9. Argiles JM, Busquets S, Felipe A, Lopez-Soriano FJ. 2005. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int. J. Biochem. Cell Biol. 37:1084-104
10. Gullett N, Rossi P, Kucuk O, Johnstone PA. 2009. Cancer-induced cachexia: a guide for the oncologist. J. Soc. Integr. Oncol. 7:155-69
11. Prado CM, Baracos VE, McCargar LJ, et al. 2009. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin. Cancer Res. 15:2920-26
12. Antoun S, Baracos VE, Birdsell L, et al. 2010. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann. Oncol. 21(8):1594-98
13. Gordon JN, Green SR, Goggin PM. 2005. Cancer cachexia. QJM 98:779-88
14. Muscaritoli M, Anker SD, Argiles J, et al. 2010. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics." Clin. Nutr. 29:154-59
15. Baracos VE. 2006. Cancer-associated cachexia and underlying biological mechanisms. Annu. Rev. Nutr. 26:435-61
16. Mantovani G, Maccio A, Madeddu C, et al. 2010. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J. Mol. Med. 88:85-92
17. Mantovani A, Romero P, Palucka AK, Marincola FM. 2008. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371:771-83
18. Baracos VE. 2001. Management of muscle wasting in cancer-associated cachexia: understanding gained from experimental studies. Cancer 92:1669-77
19. Fearon KC, Preston T., 1990. Body composition in cancer cachexia. Infusionstherapie 17; 63-66.
20. Tisdale MJ. 2009. Mechanisms of cancer cachexia. Physiol. Rev. 89:381-410
21. Tisdale MJ. 2005. The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J. Support. Oncol. 3:209-17
22. Tisdale MJ. 2003. Pathogenesis of cancer cachexia. J. Support. Oncol. 1:159-68
23. Glass DJ. 2005. Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 37:1974-84
24. Glass DJ. 2003. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat. Cell Biol. 5:87-90
25. Muscaritoli M, Bossola M, Aversa Z, et al. 2006. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur. J. Cancer 42:31-41
26. Bodine SC, Latres E, Baumhueter S, et al. 2001. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294:1704-8
27. Gomes MD, Lecker SH, Jagoe RT, et al. 2001. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. USA 98:14440-45
28. Glass DJ. 2010. Signaling pathways perturbing muscle mass. Curr. Opin. Clin. Nutr. Metab. Care 13:225-29
29. Attaix D, Baracos VE. 2010. MAFbx/Atrogin-1 expression is a poor index of muscle proteolysis. Curr. Opin. Clin. Nutr. Metab. Care 13:223-24
30. Prado CM, Baracos VE, McCargar LJ, et al. 2007. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin. Cancer Res. 13:3264-68
31. Prado CM, Birdsell LA, Baracos VE. 2009. The emerging role of computerized tomography in assessing cancer cachexia. Curr. Opin. Support. Palliat. Care 3:269-75
32. Jetté M. 1983. Guide for Anthropometric Measurements of Canadian Adults. Montreal, Quebec, Can.: CT Management & Consultant Inc.
33. Ferro-Luzzi A, James WP. 1996. Adult malnutrition: simple assessment techniques for use in emergencies. Br. J. Nutr. 75:3-10
34. Baumgartner RN, Koehler KM, Gallagher D, et al. 1998. Epidemiology of sarcopenia among the elderly in New Mexico. Am. J. Epidemiol. 147:755-63
35. Prado CM, Lieffers JR, McCargar LJ, et al. 2008. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 9:629-35
36. Zamboni M, Mazzali G, Fantin F, et al. 2008. Sarcopenic obesity: a new category of obesity in the elderly. Nutr. Metab. Cardiovasc. Dis. 18:388-95
37. Baracos VE, Reiman T, Mourtzakis M, et al. 2010. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am. J. Clin. Nutr. 91:1133S-37S
38. MorleyJE, Baumgartner RN, Roubenoff R, etal. 2001. Sarcopenia. J. Lab. Clin. Med. 137:231-43
39. Janssen I, Heymsfield SB, Ross R. 2002. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J. Am. Geriatr. Soc. 50:889-96
40. Tanko LB, Movsesyan L, Mouritzen U, et al. 2002. Appendicular lean tissue mass and the prevalence of sarcopenia among healthy women. Metabolism 51:69-74
41. Melton LJ III, Khosla S, Crowson CS, et al. 2000. Epidemiology of sarcopenia. J. Am. Geriatr. Soc. 48:625-30
42. Gillette-Guyonnet S, Nourhashemi F, Andrieu S, et al. 2003. Body composition in French women 75+ years of age: the EPIDOS study. Mech. Ageing Dev. 124:311-16
43. Castillo EM, Goodman-Gruen D, Kritz-Silverstein D, et al. 2003. Sarcopenia in elderly men and women: the Rancho Bernardo study. Am. J. Prev. Med. 25:226-31
44. Aslani A, Smith RC, Allen BJ, et al. 2000. The predictive value of body protein for chemotherapy-induced toxicity. Cancer 88:796-803
45. Reid J, McKenna H, Fitzsimons D, McCance T. 2009. The experience of cancer cachexia: a qualitative study of advanced cancer patients and their family members. Int. J. Nurs. Stud. 46:606-16
46. McClement S. 2005. Cancer anorexia-cachexia syndrome: psychological effect on the patient and family. J. Wound Ostomy Continence Nurs. 32:264-68
47. Strasser F, Palmer JL, Schover LR, et al. 2006. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 107:2949-57
48. TchekmedyianNS, Cella D. 1995. Clinical usefulness of quality-of-life evaluations: the case of anorexia. Contemp. Oncol. 20:30-33
49. Cella D, Bonomi AE, Leslie WT, et al. 1993. Quality of life and nutritional well-being: measurement and relationship. Oncology 7:105-11
50. Reid J, McKenna HP, Fitzsimons D, McCance TV. 2009. An exploration of the experience of cancer cachexia: what patients and their families want from healthcare professionals. Eur. J. Cancer Care (Engl.) 19(5):682-89
51. MacDonald N, Easson AM, Mazurak VC, et al. 2003. Understanding and managing cancer cachexia. J. Am. Coll. Surg. 197:143-61
52. Ryan JL, Carroll JK, Ryan EP, et al. 2007. Mechanisms of cancer-related fatigue. Oncologist 12:22-34
53. Ribaudo JM, Cella D, Hahn EA, et al. 2000. Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual. Life Res. 9:1137-46
54. Webster K, Cella D, Yost K 2003. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual. Life Outcomes 1:79
55. Behl D, Jatoi A. 2007. Pharmacological options for advanced cancer patients with loss of appetite and weight. Expert Opin. Pharmacother. 8:1085-90
56. Klein S, Kinney J, Jeejeebhoy K, et al. 1997. Nutrition support in clinical practice: review of published data and recommendations for future research directions. Summary of a conference sponsored by the National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition. Am. J. Clin. Nutr. 66:683-706
57. Megace® ES (megestrol acetate oral suspension). 2008. Full prescribing information, Par Pharmaceutical Companies, Inc., Spring Valley, NY. Available at http://www.megacees.com/PDF/ Megace-ES-Portrait-PI.pdf
58. Murphy KT, Lynch GS. 2009. Update on emerging drugs for cancer cachexia. Expert Opin. Emerg. Drugs 14:619-32
59. Mantovani G, Madeddu C. 2009. Cancer cachexia: medical management. Support. Care Cancer 18(1):1-9
60. Loprinzi CL, Michalak JC, Schaid DJ, et al. 1993. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J. Clin. Oncol. 11:762-67
61. Simons JP, Schols AM, Hoefnagels JM, et al. 1998. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Cancer 82:553-60
62. Mantovani G, Maccio A, Madeddu C,etal. 2010. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 15:200-11
63. Loprinzi CL, Kugler JW, Sloan JA, et al. 1999. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J. Clin. Oncol. 17:3299-306
64. Evans WJ. 2007. Editorial: Megestrol acetate use for weight gain should be carefully considered. J. Clin. Endocrinol. Metab. 92:420-21
65. Gordon JN, Trebble TM, Ellis RD, et al. 2005. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54:540-45
66. Basaria S, WahlstromJT, Dobs AS. 2001. Clinical review 138: anabolic-androgenic steroid therapy in the treatment of chronic diseases. J. Clin. Endocrinol. Metab. 86:5108-17
67. Oxandrin® (oxandrolone tablets, USP) 2005. Full prescribing information, Savient Pharmaceuticals, Inc., East Brunswick, NJ. Available at: http://www.savientpharma.com/pdf/Oxandrin10mgand2% 205mgPI.pdf.
68. Bhasin S, Calof OM, Storer TW, et al. 2006. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat. Clin. Pract. Endocrinol. Metab. 2:146-59
69. Gao W, Dalton JT. 2007. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov. Today 12:241-48
70. Gao W, Kim J, Dalton JT. 2006. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm. Res. 23:1641-58
71. MohlerML, Bohl CE, Jones A, et al. 2009. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J. Med. Chem. 52:3597-617
72. Narayanan R, Mohler ML, Bohl CE, et al. 2008. Selective androgen receptor modulators in preclinical and clinical development. Nucl. Recept. Signal 6:e010
73. Gao W, Bohl CE, Dalton JT. 2005. Chemistry and structural biology of androgen receptor. Chem. Rev. 105:3352-70
74. Zilbermint MF, Dobs AS. 2009. Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia. Future Oncol. 5:1211-20
75. Segal S, Narayanan R, Dalton JT. 2006. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin. Investig. Drugs 15:377-87
76. Evans WJ, Smith MR, Morley JE, et al. 2007. Ostarine increases lean body mass and improves physical performance in healthy elderly subjects: implications for cancer cachexia patients [Abstract 9119]. J. Clin. Oncol. 25:522S
77. Garcia JM, Polvino WJ. 2009. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm. IGF Res. 19:267-73
78. Garcia J, Boccia RV, Graham C, et al. 2007. A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia [Abstract 9133]. J. Clin. Oncol. 25:525S
79. Kwak KS, Zhou X, Solomon V, et al. 2004. Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alpha-II during cancer cachexia. Cancer Res. 64:8193-98
80. Khan ZH, Simpson EJ, Cole AT, et al. 2003. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment. Pharmacol. Ther. 17:677-82
81. Wiedenmann B, Malfertheiner P, Friess H, et al. 2008. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J. Support. Oncol. 6:18-25
82. Goldberg RM, Loprinzi CL, Mailliard JA, et al. 1995. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 13:2856-59
83. Lesser GJ, Case D, Ottery F, et al. 2008. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy. Abstr. 9513. J. Clin. Oncol. 26:505S